Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2026 ,inter alia, to consider and approve 1. Un-audited Financial results for the quarter and half year ended September 30, 2026. 2. Limited Review Report for the quarter ended September 30, 2026. 3. Any other business with the permission of the Chair.

VIRUPAKSHA To Date: 05.11.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Intimation of the Board Meeting to be held on Tuesday, 10" November, 2026 Pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the Exchange that a Board Meeting of the Company will be held on Tuesday, 10" November, 2026 at the Corporate office of the Company to consider inter alia, the following: 1. Un-audited Financial results for the quarter and half year ended September 30, 2026. 2. Limited Review Report for the quarter ended September 30, 2026. 3. Any other business with the permission of the Chair. This is for the information and records of the Exchange, please. Thanking you. Yours sincerely, For Oxygenta Pharmaceutical Limited Kumkum Bajaj Company Secretary & Compliance Officer OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An IS0 9001:2015, SO 14001:2018 and ISO 45001:2015 Cerified Company) Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad — 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com, Phone 040-23073417, CIN: L24110TG1990PLC012038